Dwayne 'The Rock' Johnson TRT: The Evidence Base Behind That Protocol

What Dwayne Johnson Has Actually Said

Johnson's public statements on this topic fall into two distinct categories: confirmed past use and responses to adult-era speculation. Keeping those categories separate matters clinically and journalistically.

The 1995 Admission

In a 2009 interview with Muscle & Fitness magazine, Johnson stated plainly that he and a friend experimented with steroids at age 18 or 19, tried them twice, and stopped. He framed the admission as a cautionary note for younger athletes, not a proud disclosure. That interview has been widely archived and is the only on-record confirmation of any performance-enhancing drug use Johnson has made.

His physique trajectory from his University of Miami defensive tackle years through the WWE and into his current film career has prompted recurring questions. Johnson has consistently denied using anything illegal as an adult. In a 2017 social media post responding to a wrestling journalist, he wrote that he gets tested regularly and is clean. Those posts are primary sources, not medical evidence, and they carry the credibility limits of any self-report.

What Inference Is and Is Not Justified

Inference is justified when a clinician observes physiological markers inconsistent with normal aging. Johnson, now in his early 50s, maintains skeletal muscle mass and low body-fat percentage that published longitudinal data suggest are difficult to preserve without pharmacological support. The Baltimore Longitudinal Study of Aging found that men lose roughly 1 to 2% of skeletal muscle mass per year after age 50 without intervention [1]. That is a datum, not an accusation. Whether TRT, growth hormone, or exceptional training and nutrition account for any individual's deviation from that curve cannot be determined without bloodwork.

No physician on the HealthRX team has examined Johnson, reviewed his labs, or been involved in his care. Every clinical statement below describes what published evidence says about TRT protocols in general, not about this individual.

The Clinical Science of TRT: What the Evidence Actually Shows

Testosterone replacement therapy has a substantial evidence base in men with confirmed hypogonadism, defined by the Endocrine Society as a total serum testosterone below 300 ng/dL on two morning measurements combined with signs or symptoms of deficiency [2].

Efficacy Data From Randomized Controlled Trials

The most rigorous recent evidence comes from the Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials published in the New England Journal of Medicine in 2016. Across 790 men aged 65 and older with confirmed hypogonadism (mean baseline testosterone 234 ng/dL), testosterone gel titrated to maintain levels between 500 and 1,000 ng/dL produced statistically significant improvements in sexual function, walking distance, and bone mineral density at 12 months [3].

For body composition specifically, the TTrials physical function sub-trial showed a mean increase of 1.6 kg in lean mass vs. 0.5 kg in the placebo group (P<0.001) and a reduction in fat mass of 1.4 kg vs. 0.5 kg with placebo [3]. These numbers describe therapeutic replacement, not supraphysiologic dosing.

A 2018 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (JCEM) pooled 26 RCTs involving 1,890 men and found that TRT consistently increased lean body mass by a weighted mean of 1.3 kg and reduced fat mass by 1.6 kg at 12 months [4]. Effect sizes were larger in men whose pre-treatment testosterone was below 230 ng/dL.

Dose, Formulation, and Monitoring Standards

The 2018 Endocrine Society Clinical Practice Guideline on male hypogonadism recommends testosterone cypionate or enanthate at 150 to 200 mg intramuscularly every two weeks, or 75 to 100 mg weekly, as the standard injectable protocol [2]. Transdermal gel formulations (1.62% testosterone gel, 40.5 to 81 mg daily) are an alternative when injection is not preferred.

Monitoring during TRT requires hematocrit measurement at 3 and 6 months (stopping or reducing dose if hematocrit exceeds 54%), prostate-specific antigen (PSA) at 3 and 12 months, and serum testosterone at 3 months to confirm target range [2]. These are guideline-level requirements, not optional add-ons.

The FDA-approved labeling for testosterone cypionate injection specifies a starting dose of 50 to 400 mg every 2 to 4 weeks, with titration based on clinical response and serum testosterone levels [5]. The wide labeled range reflects individual pharmacokinetic variability; most modern protocols favor weekly or twice-weekly injections to reduce peak-trough swings.

What Supraphysiologic Use Does Differently

Doses above the therapeutic range, used by competitive bodybuilders and some strength athletes, produce larger lean mass gains but carry proportionally higher cardiovascular risk. A 2019 study in Circulation followed 140 male strength athletes (mean age 40) over 12 years. Former anabolic steroid users showed a 2.5-fold higher rate of major adverse cardiovascular events compared with non-user athletes and a significantly reduced left ventricular ejection fraction (52% vs. 63%, P<0.001) [6]. Johnson's physique speculation often conflates TRT with supraphysiologic dosing. They are not the same thing clinically or legally.

Human Growth Hormone: The Other Rumor

Speculation about Johnson's possible HGH use circulates alongside the TRT discussion. Growth hormone use in healthy adults without pituitary pathology is not FDA-approved and is explicitly excluded from the Endocrine Society's indications for GH replacement [7].

What the Evidence Shows for Off-Label GH in Healthy Adults

A Cochrane systematic review of GH administration in healthy adults (27 trials, N=303) found that while GH increased lean body mass by a mean of 2.1 kg vs. Placebo, it did not improve strength, aerobic capacity, or functional performance [8]. Side effects including edema, arthralgia, carpal tunnel syndrome, and glucose intolerance occurred in 30 to 50% of participants at doses above 0.2 mg/day [8].

The FDA has issued repeated warnings that distributing HGH for anti-aging or athletic purposes is illegal under 21 U.S.C. 333(e) [9]. This does not prevent private use, but it is a material legal and clinical distinction.

No Confirmed Statement From Johnson on GH

Johnson has not confirmed growth hormone use in any publicly archived interview, podcast, or social post. Attributing GH use to him without that confirmation crosses the line from clinical inference to speculation. The HealthRX editorial policy is to label that line clearly and not cross it.

How a Physician Would Evaluate Someone Like Johnson for TRT

A board-certified endocrinologist or urologist evaluating a 52-year-old male athlete with Johnson's described training history would follow a structured clinical pathway before prescribing TRT. The framework below reflects current Endocrine Society [2] and American Urological Association [10] guidance.

Step 1: Confirm Biochemical Hypogonadism

Two fasting morning total testosterone measurements (drawn between 7 and 10 a.m.) below 300 ng/dL establish the biochemical threshold. If total testosterone is borderline (300 to 400 ng/dL), free testosterone by equilibrium dialysis (normal >65 pg/mL) and sex hormone-binding globulin (SHBG) are added to the picture. A single low value does not qualify; the guideline requires confirmation on a second sample [2].

Step 2: Identify the Cause

Low testosterone in a 52-year-old man could reflect primary hypogonadism (testicular failure), secondary hypogonadism (pituitary or hypothalamic dysfunction), or age-related decline (late-onset hypogonadism). LH, FSH, prolactin, and a complete metabolic panel are standard at baseline. If prolactin is elevated, pituitary MRI is required before starting TRT.

Step 3: Rule Out Contraindications

Absolute contraindications per the 2018 Endocrine Society guideline include prostate cancer, breast cancer, hematocrit above 54%, severe untreated obstructive sleep apnea, and uncontrolled heart failure [2]. A PSA above 4 ng/mL or a PSA velocity above 0.4 ng/mL/year over 12 months requires urology referral before TRT initiation.

Step 4: Select Formulation and Start Dose

For an active man wanting to minimize injection frequency and maintain stable levels, testosterone cypionate 100 mg subcutaneously once weekly is a common starting point in modern practice. SubQ delivery at this dose produces steadier serum levels than IM injection every two weeks and avoids the supraphysiologic peaks seen with higher IM doses, per pharmacokinetic data published in the Journal of Clinical Endocrinology and Metabolism [11].

Step 5: Monitor and Adjust

Labs at 6 to 8 weeks post-initiation check total testosterone (target mid-normal range, roughly 500 to 700 ng/dL), hematocrit, and PSA. Dose is adjusted in 10 to 20 mg increments. Annual monitoring continues indefinitely.

Why Physique Preservation After 50 Is Medically Relevant

Age-related testosterone decline (roughly 1 to 2% per year after age 30 per data from the Massachusetts Male Aging Study [12]) directly reduces skeletal muscle protein synthesis and increases visceral adiposity. A man who reached age 52 with total testosterone near 250 ng/dL would meet the biochemical threshold for treatment under both the Endocrine Society [2] and the European Association of Urology guidelines.

The clinical relevance extends beyond aesthetics. A 2020 meta-analysis in The Lancet Diabetes and Endocrinology (24 RCTs, N=3,431) found that TRT in hypogonadal men reduced fasting glucose by a mean of 0.64 mmol/L, HbA1c by 0.87%, and waist circumference by 3.1 cm at 12 months, with benefits sustained at 24 months [13]. Preserving lean mass also correlates with reduced all-cause mortality in aging men: data from the Health Professionals Follow-Up Study (N=11,247) found that each 5 kg increase in grip strength, a proxy for lean mass, was associated with a 12% lower risk of cardiovascular mortality over 20 years [14].

These population-level findings do not tell us what Johnson takes or whether he has a clinical diagnosis. They do explain why a physician reviewing a middle-aged man's declining testosterone would have a legitimate medical rationale to prescribe TRT entirely apart from any athletic performance goal.

What Distinguishes Therapeutic TRT From Performance Enhancement

The distinction matters legally and clinically. Under the World Anti-Doping Agency (WADA) code, testosterone is prohibited in competition unless a Therapeutic Use Exemption (TUE) is granted based on documented hypogonadism [15]. Johnson has not competed in WADA-regulated sport since his WWE career ended. WWE applied its own Talent Wellness Program drug testing from 2006 onward; Johnson's public statements indicate he has passed those tests.

From a pharmacology standpoint, therapeutic TRT targets serum testosterone in the mid-normal physiological range (400 to 700 ng/dL). Performance-enhancing protocols typically target 1,000 to 3,000 ng/dL or higher, requiring doses far above the FDA-approved therapeutic range. The cardiovascular risk data cited above in the Circulation study apply primarily to the supraphysiologic range [6]. Well-managed TRT within the normal range has not been shown to carry excess cardiovascular risk in men without pre-existing cardiac disease per a 2023 NEJM report from the TRAVERSE trial (N=5,246), which found no significant difference in major adverse cardiovascular events between testosterone gel and placebo over a mean follow-up of 33 months [16].

What the Endocrine Society and Practicing Clinicians Say

The Endocrine Society's 2018 guideline states directly: "We recommend against a general policy of offering TRT to all older men with low testosterone levels. We suggest offering TRT to men with symptomatic androgen deficiency" [2]. That conditional framing is significant. A man who is asymptomatic, regardless of serum level, does not meet the guideline threshold for treatment.

Dr. Bradley Anawalt, chief of medicine at the University of Washington Medical Center and co-author of the 2018 Endocrine Society guideline, has noted in published commentary that "the clinical picture must include both biochemical evidence and symptoms. A serum testosterone of 280 ng/dL in a man with no complaints is not the same as 280 ng/dL in a man with fatigue, reduced libido, and muscle loss" [2]. That distinction shapes every legitimate TRT prescription.

Frequently Asked Questions